Breast Cancer Incidence, 1980 2006: Combined Roles of Menopausal Hormone Therapy, Screening Mammography, and Estrogen Receptor Status
JNCI Journal of the National Cancer InstitutePublished 24 July 2007
Andrew G. Glass, James V. Lacey, J. Daniel Carreon, Robert N. Hoover
Citations437
SJR quartileQ1
SJR score5.70
SNIP2.66
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
From 1980 through 2006, quantitative and qualitative trends in breast cancer incidence rates, particularly for ER+ tumors, parallel major changes in patterns of mammography screening and use of menopausal hormone therapy.
Abstract
From 1980 through 2006, quantitative and qualitative trends in breast cancer incidence rates, particularly for ER+ tumors, parallel major changes in patterns of mammography screening and use of menopausal hormone therapy.
Keywords
MedicineBiochemistry, Genetics and Molecular Biology
JAMARisks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled Trial
15,680 Citations2002Jacques E. Rossouw
Overall health risks exceeded benefits from use of combined estrogen plus progestin for an average 5.2-year follow-up among healthy postmenopausal US women, and the results indicate that this regimen should not be initiated or continued for primary prevention of CHD.
JAMARandomized Trial of Estrogen Plus Progestin for Secondary Prevention of Coronary Heart Disease in Postmenopausal Women
6,229 Citations1998Stephen B. Hulley
Treatment with oral conjugated equine estrogen plus medroxyprogesterone acetate did not reduce the overall rate of CHD events in postmenopausal women with established coronary disease and the treatment did increase the rate of thromboembolic events and gallbladder disease.
Statistics in MedicinePermutation tests for joinpoint regression with applications to cancer rates
6,069 Citations2000Hyune-Ju Kim, Michael P. Fay +2 more
A joinpoint regression model is applied to describe continuous changes in the recent trend and the grid-search method is used to fit the regression function with unknown joinpoints assuming constant variance and uncorrelated errors.
The LancetBreast cancer and hormone-replacement therapy in the Million Women Study
2,971 Citations2003Valerie Beral
Current use of HRT is associated with an increased risk of incident and fatal breast cancer; the effect is substantially greater for oestrogen-progestagen combinations than for other types of H RT.
New England Journal of MedicineEffect of Screening and Adjuvant Therapy on Mortality from Breast Cancer
2,498 Citations2005Donald A. Berry, Kathleen A. Cronin +8 more
Seven statistical models showed that both screening mammography and treatment have helped reduce the rate of death from breast cancer in the United States.
The LancetBreast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer
2,461 Citations1997Calle, E.E., Heath Jr., C.W. +194 more
Of the many factors examined that might affect the relation between breast cancer risk and use of HRT, only a woman's weight and body-mass index had a material effect: the increase in the relative risk of breast cancer diagnosed in women using HRT and associated with long durations of use in current and recent users was greater for women of lower than of higher weight or body- mass index.
New England Journal of MedicineThe Decrease in Breast-Cancer Incidence in 2003 in the United States
977 Citations2007Peter M. Ravdin, Kathleen A. Cronin +6 more
An initial analysis of data from the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) registries shows that the age-adjusted incidence rate of breast cancer in women in the United States fell sharply in 2003, as compared with the rate in 2002.
JAMANational Use of Postmenopausal Hormone Therapy
971 Citations2004Adam L. Hersh, Marcia L. Stefanick +1 more
Clinical practice responded rapidly to recent evidence of harms associated with hormone therapy, and many patients have discontinued hormone therapy or are tapering to lower doses.
Statistics in MedicineKim H‐J, Fay MP, Feuer EJ, Midthune DN, ‘ Permutation tests for joinpoint regression with applications to cancer rates’. <i>Statistics in Medicine</i> 2000 <b>19</b>:335–351
890 Citations2001Hyune‐Ju Kim
The original article to which this Correction refers was published in Statistics in Medicine 2000; 19:335–351.
Breast Cancer Research and TreatmentEstrogen Receptor Breast Cancer Phenotypes in the Surveillance, Epidemiology, and End Results Database
582 Citations2002William F. Anderson, Nilanjan Chatterjee +2 more
JAMAPeriodic Breast Cancer Screening in Reducing Mortality From Breast Cancer
475 Citations1971Sam Shapiro
The 3 1/2-year case fatality rates among women with histologically confirmed breast cancers reinforce the impression that screening leads to lowered mortality, and more time is needed to establish whether the effect of the screening program is short-term or long-term.
CancerAnnual report to the nation on the status of cancer, 1975–2003, featuring cancer among U.S. Hispanic/Latino populations
428 Citations2006Holly L. Howe, Xiao‐Cheng Wu +10 more
The American Cancer Society, Centers for Disease Control and Prevention, National Cancer Institute, and North American Association of Central Cancer Registries collaborate annually to provide U.s. cancer information, this year featuring the first comprehensive compilation of cancer information for U.S. Latinos.
Obstetrical & Gynecological SurveyEffect of Screening and Adjuvant Therapy on Mortality From Breast Cancer
389 Citations2006Donald A. Berry, Kathleen A. Cronin +8 more
Seven statistical models showed that both screening mammography and treatment have helped reduce the rate of death from breast cancer in the United States.
Breast Cancer ResearchRecent trends in breast cancer incidence rates by age and tumor characteristics among U.S. women
352 Citations2007Ahmedin Jemal, Elizabeth Ward +1 more
The sharp decrease in incidence from 2002 to 2003 that occurred in women 50 to 69 years old who predominantly, but not exclusively, had ER+ tumors may reflect the early benefit of the reduced use of hormone replacement therapy.
BMJRate of over-diagnosis of breast cancer 15 years after end of Malmö mammographic screening trial: follow-up study
343 Citations2006Sophia Zackrisson, Ingvar Andersson +3 more
Conclusions on over-diagnosis of breast cancer in the Malmö mammographic screening trial can be drawn mainly for women aged 55-69 years at randomisation whose control groups were never screened.
Annals of Internal MedicineChanges in the Use of Postmenopausal Hormone Therapy after the Publication of Clinical Trial Results
315 Citations2004Jennifer S. Haas, Celia P. Kaplan +2 more
Whether the use of hormone therapy has changed among postmenopausal women as a result of the publication of the HERS and the WHI is examined, and whether patterns of use differ by patient characteristics is examined.
JNCI Journal of the National Cancer InstituteBreast Tumor Characteristics as Predictors of Mammographic Detection: Comparison of Interval- and Screen-Detected Cancers
264 Citations1999Peggy L. Porter, A. Y. El-Bastawissi +8 more
It is indicated that screening mammography may miss tumors of lobular or mucinous histology and some rapidly proliferating, high-grade tumors.
The American Journal of MedicineEstrogens and progestins: background and history, trends in use, and guidelines and regimens approved by the US Food and Drug Administration
206 Citations2005Marcia L. Stefanick
FDA guidelines regarding treatment indications for vasomotor symptoms, vaginal atrophy, and osteoporosis prevention have resulted in approval of several estrogen (and progestin) formulations, doses, and routes of administration, thereby providing many options for women who seek conventional therapy.
CancerReported drop in mammography
201 Citations2007Nancy Breen, Kathleen A. Cronin +5 more
Whether recent use of mammography has dropped nationally is ascertain to ascertain whether timely screening with mammography can prevent a substantial number of deaths from breast cancer.
JNCI MonographsBuilding a Research Consortium of Large Health Systems: The Cancer Research Network
176 Citations2005Edward H. Wagner
The challenges of constructing a productive consortium of large health systems, and the CRN's responses are described, with suggestions for the development, execution, and management of multisystem population laboratories.
British Journal of CancerBreast screening, prognostic factors and survival – results from the Swedish two county study
176 Citations1991SW Duffy, Làszló Tabár +5 more
Examination of the relationships among the prognostic factors and mode of detection indicates that malignancy grade, as a measure of inherent malignant capacity, evolves as a tumour grows.
JAMAPromotion and Prescribing of Hormone Therapy After Report of Harm by the Women’s Health Initiative
170 Citations2004Sumit R. Majumdar
There was a substantial decline in promotional spending for hormone therapy, particularly for the agents most directly implicated in the WHI E+P trial, and more recently, promotional efforts have increased,particularly for lower-dose Prempro, a resurgence associated with modestly increased prescriptions for this newer agent.
Journal of Clinical OncologyRecent Declines in Hormone Therapy Utilization and Breast Cancer Incidence: Clinical and Population-Based Evidence
161 Citations2006Christina A. Clarke, Sally L. Glaser +4 more
To better understand the possible impact from changes in HT on breast cancer in larger populations, recent secular trends in HT use and breast cancer incidence are compared in available clinical and population-based data resources, including recently released cancer registry data for the year 2004.
American Journal of EpidemiologyGraphical Presentation of Trends in Rates
160 Citations1995Susan S. Devesa, Janet R Donaldson +1 more
The authors conclude that a graph should be designed and studied with care, clearly reflect the truth, convey information, and make a point without overemphasizing in the plotting of odds ratios or relative risks.
JNCI Journal of the National Cancer InstituteDeclines in Invasive Breast Cancer and Use of Postmenopausal Hormone Therapy in a Screening Mammography Population
155 Citations2007Karla Kerlikowske, Diana L. Miglioretti +3 more
The finding of a statistically significant decline in the rate of ER-positive invasive breast cancer in a screening mammography population after the start of a concomitant substantial decline in postmenopausal hormone therapy use suggests that a decline in screenings mammography rates is unlikely to account for the recent decline in US breast cancer incidence.
CancerAssociation of hormone replacement therapy to estrogen and progesterone receptor status in invasive breast carcinoma
138 Citations2004Wendy Y. Chen, Susan E. Hankinson +4 more
It is hypothesized that HRT may be associated with the development of estrogen receptor (ER)‐ positive/progesterone receptor (PR)‐positive breast carcinoma more so than with theDevelopment of ER‐negative/PR‐negative breast carcinomas.
EpidemiologyBreast Cancer Risk and Duration of Estrogen Use
99 Citations1994Karen Steinberg, S. Jay Smith +2 more
From a homogeneous group of case-control studies using community controls that analyzed the effect of conjugated equine estrogens, it is estimated that the risk of breast cancer after 10 years of estrogen use increased by at least 15% and up to 29%.
JNCI Journal of the National Cancer InstituteRising Incidence of Breast Cancer: Relationship to Stage and Receptor Status
89 Citations1990Andrew G. Glass, Robert N. Hoover
Overall, incidence of breast cancer incidence rose 45% during this period, and the largest increases occurred in women 60 years of age or older and in those 45-59, while the rate in women aged 20-44 has remained essentially unchanged.
Breast Cancer Research and TreatmentAssessing the impact of screening mammography: breast cancer incidence and mortality rates in Connecticut (1943–2002)
82 Citations2006William F. Anderson, Ismail Jatoi +1 more
Along with increases in incidence rates for early-stage tumors, rates for late-stage disease and breast cancer mortality declined following widespread screening mammography, consistent with effective early detection and improved treatment over time.
International Journal of CancerIncreased incidence of invasive breast cancer after the introduction of service screening with mammography in Sweden
79 Citations2005Håkan Jönsson, Robert Johansson +1 more
The findings were further confirmed by the observation of a disappearance in the screened population of the notch in the increasing trend of age‐specific breast cancer incidence for the ages after menopause, which could indicate hormone‐related retardation in tumour growth around menopsause.
PubMedEstrogen-progestin replacement and risk of breast cancer
51 Citations2000C Schairer, Jay H. Lubin
American Journal of EpidemiologyAre Long-term Hormone Replacement Therapy Users Different from Short-term and Never Users?
42 Citations1999Diana S.M. Buist, Andrea Z. LaCroix +2 more
MaturitasCorrelates of hormone replacement therapy use in Italian women, 1992–1996
32 Citations1999Francesça Chiaffarino, Fabio Parazzini +5 more
HRT use was directly associated with early age at menopause and surgical menophere and inversely related with measures of body weight, and women of higher socioeconomic status or education reported more frequent HRT use and nulliparae and smokers were also more likely to use HRT.
JNCI Journal of the National Cancer InstituteChanging Incidence of Breast Cancer
21 Citations1988A. GEASS, Robert N. Hoover
JAMASerologic Testing for Lyme Disease—Reply
19 Citations2000Steven E. Schutzer
It is concluded that the estrogen-progestin regimen is associated with higher risks of breast cancer than estrogen alone, however, several aspects of the study deserve careful consideration.